← Back to Home

Full ZEUS Results Released: IL-6 Antibody Did Not Reduce Cardiovascular Events; Infection and Thrombosis Signals Emerge

A trial involving more than 6,300 patients with cardiovascular disease and chronic kidney disease reveals a gap between suppressing inflammation and improving outcomes. Newly released details add to safety concerns and make the question of which patients should receive anti-inflammatory therapies more pressing.

By SURL BioNews

For people with both atherosclerotic cardiovascular disease and chronic kidney disease, can lowering inflammatory signals in the blood prevent a heart attack or stroke? The phase 3 ZEUS trial did not provide an affirmative answer. The full results, presented on November 7 at the American Heart Association annual meeting and simultaneously published in The New England Journal of Medicine, further explain why the IL-6 antibody ziltivekimab failed to meet its primary efficacy endpoint and reveal differences between the groups in infections and thrombotic events.

The double-blind, randomized controlled trial, funded by Novo Nordisk, spanned 757 study sites in 38 countries and included 6,376 participants in the full analysis. All participants had established cardiovascular disease, chronic kidney disease, and high-sensitivity C-reactive protein (hsCRP) levels of at least 2 milligrams per liter, indicating a persistent inflammatory burden. In addition to their existing care, they received a monthly subcutaneous injection of 15 milligrams of ziltivekimab or placebo.

Novo Nordisk had announced in late July that the trial had failed to meet its endpoint; the full data now provide a more detailed picture. After a median follow-up of 33 months, the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 17.6% of patients in the treatment group and 17.7% in the placebo group. The hazard ratio was 0.99, with a 95% confidence interval of 0.88 to 1.11, showing no statistically significant difference. There was also no difference in all-cause mortality, and the kidney composite endpoint likewise showed no improvement.

The drug did act on its intended pathway. Ziltivekimab is a monoclonal antibody that neutralizes interleukin-6 (IL-6); in the trial, both free IL-6 and hsCRP declined, but these reductions did not translate into fewer major cardiovascular events. This gives ZEUS significance beyond the success or failure of a single drug: inflammatory markers can reflect risk, but improvements in those markers alone remain insufficient to establish that a treatment can change patients’ clinical outcomes.

The safety details further complicate the assessment of benefits and risks. The overall proportions of serious adverse events were similar between the two groups, but serious infections were more common in the treatment group. According to the full results summarized by HCPLive, serious venous thromboembolism occurred in 1.6% versus 0.6%; the proportions with platelet counts below 100 × 10⁹ per liter were 7.4% versus 3.2%. The researchers believe it remains uncertain whether the imbalance in thrombotic events arose from inhibition of the IL-6 pathway, participant characteristics, or chance.

ZEUS does not, however, rule out all anti-inflammatory strategies. Principal investigator Paul Ridker noted that previous studies of canakinumab or low-dose colchicine have shown reductions in cardiovascular events in specific populations. However, differences in where drugs act, patients’ disease stage, and their burden of comorbidities may all affect results, so previous successes cannot be directly extrapolated to another antibody.

The research team proposed that the cardiovascular and kidney disease in ZEUS participants may already have been too advanced for this intervention to alter the course of disease; this remains a hypothesis to explain the results, rather than a cause established by the trial. Whether patients with earlier-stage disease might benefit, and whether targeting the NLRP3 inflammasome further upstream in the inflammatory pathway could work, each require their own clinical trials. The central question left by the full results is how to translate measurable changes in inflammation into actual protection for patients.

References

  1. American Heart Association
  2. Novo Nordisk
  3. HCPLive
  4. STAT